Repurposing antidiabetic drugs for Alzheimer's disease: A review of preclinical and clinical evidence and overcoming challenges
Jacky Tran,
Sneh Parekh,
Julia Rockcole
и другие.
Life Sciences,
Год журнала:
2024,
Номер
355, С. 123001 - 123001
Опубликована: Авг. 22, 2024
Язык: Английский
Intraparenchymal delivery of adeno-associated virus vectors for the gene therapy of neurological diseases
Expert Opinion on Biological Therapy,
Год журнала:
2024,
Номер
24(8), С. 773 - 785
Опубликована: Июль 27, 2024
In
gene
therapy
with
adeno-associated
virus
(AAV)
vectors
for
diseases
of
the
central
nervous
system,
can
be
administered
into
blood
vessels,
cerebrospinal
fluid
space,
or
brain
parenchyma.
When
transfer
to
a
large
area
is
required,
first
two
methods
are
used,
but
in
which
local
expected
effective,
directly
Язык: Английский
Repurposing of dipeptidyl peptidase FDA-approved drugs in alzheimer’s disease using network pharmacology and in-silico approaches
Computational Biology and Chemistry,
Год журнала:
2025,
Номер
116, С. 108378 - 108378
Опубликована: Фев. 8, 2025
Язык: Английский
Molecular mechanisms and biomarkers in neurodegenerative disorders: a comprehensive review
Molecular Biology Reports,
Год журнала:
2025,
Номер
52(1)
Опубликована: Март 26, 2025
Язык: Английский
Emerging Gene Therapies for Alzheimer’s and Parkinson’s Diseases: An Overview of Clinical Trials and Promising Candidates
Cureus,
Год журнала:
2024,
Номер
unknown
Опубликована: Авг. 16, 2024
Gene
therapy
as
a
disease-modifying
therapeutic
approach
for
neurodegenerative
diseases,
such
Alzheimer's
disease
(AD)
and
Parkinson's
(PD),
is
promising
avenue.
Promising
results
in
the
preclinical
studies
involving
rodents
nonhuman
primates
utilizing
gene
have
led
to
multiple
clinical
trials
evaluating
various
genes
of
interest
AD
PD.
In
AD,
are
assessing
brain-derived
neurotrophic
factor
(BDNF)
other
targets
apolipoprotein
E2
(APOE2)
human
telomerase
reverse
transcriptase
(hTERT).
PD,
delivering
factors,
glial
cell
line-derived
(GDNF).
Additionally,
enzymes
aromatic
L-amino
acid
decarboxylase
(AADC)
glutamic
(GAD)
also
being
evaluated
All
these
primarily
utilized
adeno-associated
virus
(AAV)
deliver
above
transgene
interest.
This
review
summarizes
current
It
discusses
challenges
opportunities
associated
with
PD
ongoing
developments
related
increasing
safety
efficacy
long-term
outcomes,
which
include
evaluation
serotypes
administration
routes.
comprehensive
emphasizes
translating
findings
into
trials,
further
directions,
potential
this
alleviate
disease.
Язык: Английский
Exploring the Therapeutic Potential of DPP4 Inhibitors in Alzheimer's Disease: Molecular Insight and Clinical Outcome
Cureus,
Год журнала:
2024,
Номер
unknown
Опубликована: Окт. 29, 2024
Alzheimer's
disease
(AD)
is
a
progressive
neurodegenerative
disorder
characterized
by
amyloid-beta
(Aβ)
plaques,
neurofibrillary
tangles,
and
cognitive
decline.
Given
the
shared
neuropathophysiological
traits
between
AD
type
2
diabetes
mellitus
(T2DM),
repurposing
antidiabetic
medications,
such
as
dipeptidyl
peptidase
4
inhibitors
(DPP4i),
has
emerged
promising
therapeutic
strategy.
This
review
comprehensively
evaluates
preclinical
clinical
evidence
supporting
potential
of
DPP4i
in
preventing
or
treating
modulating
Aβ
tau
pathology,
improving
function,
reducing
neuroinflammation
oxidative
stress,
promoting
neuronal
survival.
The
beneficial
effects
are
likely
mediated
through
modulation
insulin
signaling,
anti-inflammatory
antioxidant
properties,
glucagon-like
peptide-1
(GLP-1)
upregulation,
amyloidogenic
pathway.
While
further
research
needed
to
establish
their
efficacy
patients,
offers
avenue
for
intervention
this
devastating
disease.
Язык: Английский
From Fundamentals to Innovation in Alzheimer’s Disease: Molecular Findings and Revolutionary Therapies
Mădălina Georgeta Sighencea,
R. Popescu,
Simona Trifu
и другие.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(22), С. 12311 - 12311
Опубликована: Ноя. 16, 2024
Alzheimer's
disease
(AD)
is
a
global
health
concern
and
the
leading
cause
of
dementia
in
elderly.
The
prevalence
this
neurodegenerative
condition
projected
to
increase
concomitantly
with
increased
life
expectancy,
resulting
significant
economic
burden.
With
very
few
FDA-approved
disease-modifying
drugs
available
for
AD,
there
an
urgent
need
develop
new
compounds
capable
impeding
progression
disease.
Given
unclear
etiopathogenesis
review
emphasizes
underlying
mechanisms
condition.
It
explores
not
only
well-studied
aspects,
such
as
accumulation
Aβ
plaques
neurofibrillary
tangles,
but
also
novel
areas,
including
glymphatic
lymphatic
pathways,
microbiota
gut-brain
axis,
serotoninergic
autophagy
alterations,
vascular
dysfunction,
metal
hypothesis,
olfactory
pathway,
oral
health.
Furthermore,
potential
molecular
targets
arising
from
all
these
have
been
reviewed,
along
promising
approaches
nanoparticle-based
therapy,
neural
stem
cell
transplantation,
vaccines,
CRISPR-Cas9-mediated
genome
editing
techniques.
Taking
into
account
overlap
various
mechanisms,
individual
combination
therapies
emerge
future
direction
AD
strategy.
Язык: Английский
Oligodendrocytes, the Forgotten Target of Gene Therapy
Cells,
Год журнала:
2024,
Номер
13(23), С. 1973 - 1973
Опубликована: Ноя. 28, 2024
If
the
billions
of
oligodendrocytes
(OLs)
populating
central
nervous
system
(CNS)
patients
could
express
their
feelings,
they
would
undoubtedly
tell
gene
therapists
about
frustration
with
other
neural
cell
populations,
neurons,
microglia,
or
astrocytes,
which
have
been
favorite
targets
transfer
experiments.
This
review
questions
why
OLs
left
out
most
therapy
attempts.
The
first
explanation
is
that
pathogenic
role
still
discussed
in
CNS
diseases.
Another
reason
so-called
ubiquitous
CAG,
CBA,
CBh,
CMV
promoters—widely
used
studies—are
unable
poorly
able
to
activate
transcription
episomal
transgene
copies
brought
by
adeno-associated
virus
(AAV)
vectors
OLs.
Accordingly,
expression
has
either
not
found
evaluated
studies
rodents
non-human
primates.
aims
current
are
give
rightful
place
among
cells
future
target
and
encourage
researchers
test
effect
OL
transduction
various
Язык: Английский
Development of a Herb-Based Dietary Ingredient with Potential Nootropic Properties: From Bench to Bedside
Applied Sciences,
Год журнала:
2024,
Номер
14(24), С. 11869 - 11869
Опубликована: Дек. 19, 2024
Cognitive
decline
is
a
natural
process
that
occurs
during
aging.
Several
solutions
called
nootropics
exist
can
help
mitigate
this
process.
However,
in
some
cases,
there
lack
of
scientific
evidence
on
their
potential
mechanisms
and
efficacy.
To
end,
total
nine
different
herb
extracts
with
nootropic
activity
were
evaluated.
These
tested
human
neural
stem
cell
cultures
exposed
to
oxidative
stress,
where
reactive
oxygen/nitrogen
species,
survival
trophic
factor
expression
analyzed.
Of
these
extracts,
Salvia
officinalis
(sage)
was
observed
possess
the
most
significant
effect.
Its
combination
rutin
demonstrated
additional
benefits
than
only
sage.
A
randomized,
double-blind
placebo-controlled
clinical
study
then
performed,
testing
effects
at
two
doses
for
12
weeks
healthy
volunteers
aged
50+
mild
cognitive
impairment.
As
result,
blend
significantly
improved
several
characteristics
related
memory,
particularly
memory
recall,
more
noticeable
effect
higher
dose.
Therefore,
reveals
comprising
rutin.
This
could
be
candidate
dietary
ingredient
properties.
Язык: Английский